Eli Lilly (LLY) was admonished by a California lawmaker for promoting a diabetes help center for patients who cannot afford their insulin while at the same time failing to lower prices or comply with a new state law that requires drug makers to disclose pricing details.
In a harshly worded letter sent on Monday, state Sen. Ed Hernandez, who sponsored the transparency law, criticized the company for touting its Diabetes Solution Center at the same time that prices for insulin, made by several companies, has risen dramatically in recent years. An analysis published two years ago found that the cost of insulin, on average, more than tripled — from $231 to $736 a year per patient — between 2002 and 2013.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
State Senator Hernandez’ view is probably oversimplistic,
but he should be congratulated as having his heart
in the right place for his constituents.